Sign In
Buy GALT
$2.97
-0.260 (-8.05%)
At Close: Jul 31, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
04:28pm, Tuesday, 13'th Jan 2026
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. (“Galectin” or the “Company”) (NASDAQ: GALT). Such inve
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
10:00am, Thursday, 08'th Jan 2026
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. ("Galectin" or the "Company") (NASDAQ: GALT). Such investors are adv
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with the Schall Law Firm
10:40am, Wednesday, 07'th Jan 2026
LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Galectin Therapeu
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
01:15pm, Tuesday, 06'th Jan 2026
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. (“Galectin” or the “Company”) (NASDAQ: GALT). Such inve
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT
10:00am, Thursday, 01'st Jan 2026
NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. ("Galectin" or the "Company") (NASDAQ: GALT). Such investors are adv
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm
09:54pm, Monday, 29'th Dec 2025
LOS ANGELES--(BUSINESS WIRE)---- $GALT--GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm.
Galectin Therapeutics (NASDAQ:GALT) Stock Price Passes Above 200 Day Moving Average – Here’s What Happened
04:00am, Thursday, 18'th Dec 2025
Galectin Therapeutics Inc. (NASDAQ: GALT - Get Free Report) passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $4.14 and traded as high as $
Clinical Progress Drives Galectin Shares Up Post-NAVIGATE Data
08:42am, Thursday, 04'th Dec 2025
Galectin Therapeutics (GALT) is building momentum on positive NAVIGATE trial data for belapectin, targeting compensated MASH cirrhosis. GALT reported a narrower Q3 loss due to lower R&D and operating
Galectin Therapeutics: NAVIGATE Data Validates The Fibrosis Thesis
02:44am, Wednesday, 26'th Nov 2025
Galectin Therapeutics targets MASH cirrhosis with belapectin, addressing a highly unmet need with clear mechanistic rationale and promising clinical data. GALT's NAVIGATE trial showed belapectin's 2 m
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
08:00am, Friday, 14'th Nov 2025
NORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and p
Galectin Therapeutics Inc. (GALT) Is Up 7.48% in One Week: What You Should Know
01:00pm, Friday, 12'th Sep 2025
Does Galectin Therapeutics Inc. (GALT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
08:00am, Tuesday, 02'nd Sep 2025
NORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company mana
NORCROSS, Ga., May 12, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypert
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update
08:00am, Monday, 31'st Mar 2025
NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference
08:00am, Friday, 10'th Jan 2025
NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line resu
